Current consensus guidelines recommend IL-1 and IL-6 inhibitors (e.g., anakinra and tocilizumab) as first- or second-line therapies for JIA, given their efficacy in controlling systemic inflammation and preventing disease complications [4]. The gene discussed is IL6; the disease is juvenile idiopathic arthritis.